

Strategic Competitive Intelligence and the role of the Microbiome in Immuno-Oncology

SMi reports: a comprehensive field overview and thought-provoking discussions at SMi's Immuno-Oncology Conference taking place on the 26 - 27 September in London

LONDON, UNITED KINGDOM, June 7, 2018 /EINPresswire.com/ -- In addition to the Main Conference's agenda (covering a breadth of topics and presentations ranging from case studies about Keytruda therapies to keynote addresses exploring the tumour mutation burden), SMi Group is pleased to have the expertise of the [industry leaders leading on-site interactive training programmes](#). By attending these half-day workshops, on the 25 September, attendees will formulate a deeper understanding of Strategic Competitive Intelligence and the role of the Microbiome in Immuno-Oncology.



The poster for the Immuno-Oncology Conference 2018 features a stylized graphic of blue and black horizontal lines of varying lengths on the left, resembling a DNA sequence or data visualization. The text on the right includes the event title 'Immuno-Oncology Conference' in large blue font, the dates '26 - 27 September 2018' in white on a blue background, and the location 'London, UK'. At the bottom, the website 'www.immuno-oncology-conference.com' is listed in white on a black background, with the hashtag '#immunooncologysmi' above it.

[Workshop A, 25 September, 8.30 - 12.30](#) - Strategic competitive intelligence in the Immuno-Oncology space

- Uncover opportunities and threats for your company and brand in the Immuno-Oncology space by combining the latest advancements in Strategic Competitive Intelligence.
- Get step-by-step guide on how to use CI to generate actionable insights and gain a competitive advantage over others.

This workshop is led by: Timos Papagatsias, CEO of LucidQuest - an expert with over 10 years' experience working as a strategy and intelligence consultant across the Pharma / Biotech and the Life Sciences Investment industries. Timos is now leading LucidQuest, a boutique strategic intelligence consultancy that focuses both on traditional therapy areas (oncology, haematology, immunology, CV/Met, CNS etc.) as well as on developing insights into patient centricity, digital healthcare / IoE and personalized medicine (gene and cell therapies).

[Workshop B, 25 September, 13.30 - 17.00](#) - Could the Microbiome boost Cancer Immuno-Therapy

- Further the knowledge in the advantages and challenges of developing microbiome-based treatments by looking into recent advances in understanding of the complex role of microbiome in health and disease and how microbes and the microbiota may contribute to cancer development, and responsiveness to cancer therapeutics.

This workshop is led by:

- Shahram Lavasani, CEO of ImmuneBiotech AB - skilful immunologist and PhD holder in Medical Inflammation Research. Now leading ImmuneBiotech, Shahram developed a proprietary lactobacilli library and established accurate and multiple selection technologies to

screen and design formulations for the optimal therapeutic management of the diseases.

•Ramin Massoumi, Associate Professor at Lund University, working on research into molecular targeted therapy [1]

Further details at <http://www.immuno-oncology-conference.com/einpr>

Twitter - @SMIpharm & #immunooncologysmi

LinkedIn - SMi Pharma

CONTACT:

+44 (0)20 7827 6000

ldurneva@smi-online.co.uk

[1] [portal.research.lu.se/portal/en/persons/ramin-massoumi\(ecd19c7b-c3a4-414d-a686-8bf643504064\).html](http://portal.research.lu.se/portal/en/persons/ramin-massoumi(ecd19c7b-c3a4-414d-a686-8bf643504064).html)

Lyudmyla Durneva

SMi Group

+44 (0)20 7827 6000

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.